We determined whether a 3-minute period of intense cardiac sympathetic stimulation, which is known to release neuropeptide Y (NPY), elicits a sustained poststimulatory coronary vasoconstriction in anesthetized dogs that had received propranolol. We also periodically measured the cardiac chronotropic responses to test vagal stimulations; these responses served as an index of the neuronal release of NPY. In a group of 11 animals, the coronary vascular resistance increased by 14±4% during the sympathetic stimulation. constriction in isolated human coronary arteries.'0 When infused into human coronary arteries in vivo, NPY decreases the coronary blood flow and transiently alters the electrocardiogram." The ability of NPY to constrict coronary vessels has led to the hypothesis that NPY mediates coronary spasm.5 Exogenous NPY was used in all the studies described above. The coronary vascular effects of NPY released from sympathetic nerve endings appear not to have been evaluated in vivo. The present study was therefore designed to determine the physiological role of neurally released NPY on coronary vascular resistance in vivo. The principal aims of our study were to determine whether a 3-minute period of intense cardiac sympathetic stimulation will evoke a sustained coronary vasoconstriction and will potentiate the coronary vascular responses to exogenous NE. Such effects would presumably be mediated by the release of NPY from the sympathetic nerve endings in the coronary vasculature.
also potentiates a-adrenoceptor-mediated vasoconstriction. 34 Systemic administration of NPY raises the arterial blood pressure by increasing total peripheral resistance. 5 The vasoconstrictor actions of NPY are resistant to a-adrenergic receptor blockade, and they are evident even in sympathectomized animals. These findings suggest that NPY has a direct effect on vascular smooth muscle.
The coronary vasculature is particularly sensitive to the vasoconstrictor effects of NPY. Infusion of NPY into the coronary vessels in animals causes prolonged vasoconstriction of the small resistance arteries.6-9 Intracoronary infusion of NPY in dogs elicits a pronounced coronary vasoconstriction that persists for 40-60 minutes.89 Similarly, NPY produces sustained premedicated with morphine sulfate (2 mg/kg) and anesthetized with a-chloralose (75 mg/kg). Anesthesia was maintained by the intravenous infusion of a-chloralose (5 mg/kg per hour). The trachea was intubated, and intermittent positive pressure ventilation was begun. The inspired air was supplemented with oxygen. Arterial blood gas tensions were maintained within the physiological range by adjusting the ventilation volume or rate. Metabolic acidosis was corrected by the intravenous infusion of a sodium bicarbonate solution. Body temperature was maintained at 37°C with a heat lamp.
A femoral vein was cannulated for the administration of drugs and the maintenance of fluid balance. A femoral artery was cannulated for measuring aortic pressure. The cervical vagi were isolated, doubly ligated, and sectioned to interrupt parasympathetic outflow to the heart. Bipolar hook electrodes were inserted into the cardiac end of the right vagus nerve, and the wires were connected to a stimulator (model SD9, Grass Instrument Co., Quincy, Mass.).
The chest was opened transversely at the fourth intercostal space. The right and left stellate ganglia were isolated, doubly ligated, and sectioned to eliminate sympathetic outflow to the heart. The ansae subclaviae were placed over bipolar shielded iridium electrodes (Harvard Apparatus, South Natick, Mass.), and the electrode wires were connected in parallel to an electronic stimulator (model S-4, Grass Instrument). The pericardium was opened and sutured to the chest wall to form a cradle. A bipolar electrode catheter was inserted into the atrial appendage to record an atrial electrogram. The AA interval (cardiac cycle length) was determined from the atrial electrogram by an analog computer (model 580, Electronic Associates Inc., West Long Beach, N.J.). A micromanometer (model spc-350, Millar, Houston, Tex.) was placed in the left ventricle through the apex for measurement of the left ventricular pressure and its first derivative (dP/dt).
The proximal region of the left circumflex coronary artery was dissected free from the surrounding tissue for a distance of approximately 1.5 cm. The coronary perfusion system (Figure 1 ) was primed with approximately 60 ml saline solution that contained heparin (10 units/ml). The dogs were anticoagulated by an initial dose of heparin (1,000 units/kg) and by a supplemental infusion of 10,000 units per hour via an intravenous drip. A wide-bore tube was connected to a cannula in the left femoral artery, which was the source of blood for perfusion of the left circumflex coronary artery. The perfusion pump was actuated for several minutes to prime the perfusion apparatus with blood. We continued to stimulate the vagus nerve for 10 seconds every 10 minutes for 1 hour. In this dog, 40 minutes after the sympathetic release stimulation, the response to vagal test stimulation had recovered to the control value ( Figure 3C ).
Composite data. Figure 4A shows Figure 5 shows the changes in coronary arterial perfusion pressure induced by NE infusions when the coronary vascular bed was perfused at a constant flow in a representative experiment. During the control period ( Figure 5A ), the NE infusion increased the coronary perfusion pressure by 14%. After the termination of the NE infusion, the perfusion pressure returned to the control value within 30 seconds.
Sympathetic release stimulation increased the perfusion pressure by 20%, and after cessation of stimulation, the perfusion pressure returned rapidly to the control value ( Figure SB) . Five minutes after the cessation of stimulation, an NE infusion identical to that delivered during the control period increased perfusion pressure by 13% ( Figure SC) . Figure 6A shows the mean coronary vascular responses to test infusions of NE in a group of eight dogs. During the control period, we gave three test infusions into the left circumflex coronary artery in each animal. These infusions increased coronary vascular resistance by a mean value of 14+±2%. During the sympathetic release stimulation (S in Figure 6 ), coronary vascular resistance increased by 21+5%. Five minutes after the cessation of sympathetic stimulation, the basal coronary vascular resistance did not differ from the control value. The coronary vascular responses to the NE infusions after the sympathetic release stimulation were not significantly different from the responses obtained before the sympathetic stimulation. Figure 6B shows Figure 8B ). Thus, the NE infusion given concurrently with the NPY infusion elicited an increment in coronary perfusion pressure that was approximately twice that elicited by an equivalent infusion of NE before the NPY infusion. Figure 9 shows the mean changes in coronary perfusion pressure evoked by infusions of NE and NPY, alone and concomitantly, in a group of four animals.
The "NE" curve shows the mean changes in coronary perfusion pressure evoked by three different doses of NE. All doses significantly elevated the coronary perfusion pressure, and the response increased (p<0.05) as we raised the dose of NE (Figure 9 ). The responses (not shown) to equivalent NE infusions administered during a sham infusion of NPY were not appreciably different (p=0.3) from those represented by the NE curve in Figure 9 .
The "NPY' curve in Figure 9 shows the increment in pressure evoked by the actual NPY infusion, measured just before the infusion of each dose of NE; note that in each experiment, the order of infusing the different doses of NE was randomized. Thus, the effect of the NPY did not vary appreciably with regard to the various associated NE doses.
To determine whether the NPY infusion potentiated the responses to the various doses of NE, we compared the responses to the concomitant infusions of NE and NPY with the sums of the individual responses. We found that the combined responses were significantly greater (p< 0.05) than the sums of the individual responses ( Figure 9) . Therefore, the NPY infusion did potentiate the coronary vascular responses to the NE infusions; the extent of the potentiation did not vary significantly for the various doses of NE ( Figure 9 ).
Discussion
Our experiments were designed to determine the vasomotor effects of a 3-minute period of intense sympathetic stimulation, which is known to release NPY, on the normal coronary vasculature in vivo. Our data show that sympathetic release stimulation increased coronary vascular resistance by approximately 20% (Figures 4A  and 6A ) in animals that have received propranolol. After cessation of sympathetic stimulation, however, the coronary vascular resistance rapidly returned to the control value ( Figure 4A ). Hence, sympathetic release stimulation did not have a sustained effect on coronary vascular resistance in our experiments, nor did it potentiate the effects of NE infusions on the coronary vasculature ( Figure 6A ). However, exogenous NPY did increase coronary vascular resistance in a dose-dependent manner ( Figure 7A ), and it did potentiate the responses to exogenous NE (Figures 8 and 9) . Furthermore, the vasoconstriction evoked by exogenous NPY was sustained; with the largest dose of NPY, the resistance remained increased for almost an hour ( Figure 7B ). The cardiac responses to vagal stimulation were attenuated for 30-60 minutes after sympathetic release stimulation ( Figures 4B and 6B) .
Abundant evidence has established that NPY evokes a direct sustained constriction of vascular smooth muscle2, [4] [5] [6] [7] [8] [9] [10] [11] 1316 (Figures 4A and 6A ). Other investigators, using similar preparations, observed increases in coronary vascular resistance that ranged from 10% to 25%,17-22even when coronary blood flow was measured by techniques that did not involve perivascular dissection.20,22 Therefore, we believe that destruction of the perivascular nerves during the dissection of the coronary arteries was not a critical problem in our experiments.
Abundant Collateral Coronary Circulation
The canine heart has a richer coronary collateral circulation than do the hearts of many other mammalian species. An abundant collateral circulation in our preparation may have masked the coronary vascular effects of neurally released NPY. At the beginning of each experiment, we adjusted the coronary perfusion pressure to the mean aortic pressure to minimize the confounding influence of the prevailing collateral circulation. We elected not to use a constant-pressure perfusion system in our experiments, because any reductions in flow induced by our experimental interventions might have been masked by metabolically induced adjustments (e.g., release of adenosine).
During sympathetic stimulation, the perfusion pressure increased by approximately 15 mm Hg, and the mean aortic pressure increased by approximately 8 mm Hg. Thus, the collateral coronary blood flow from the artificially perfused region (left circumflex coronary vascular bed) to the regions perfused by the cognate arteries (left anterior descending and right coronary arteries) may have been augmented. However, the pressure gradient persisted for only 3-5 minutes after cessation of stimulation. The effects of NPY on blood vessels may persist for as long as 60 minutes89; our experiments with exogenous NPY confirmed such a sustained vasoconstriction (Figure 7) . Hence, if NPY had been released from sympathetic nerve terminals into the coronary vessels in amounts that would elicit substantial vasoconstriction, the effects of NPY would have been masked for only a few minutes.
Furthermore, we observed that exogenous NPY did constrict the coronary vessels in a dose-dependent manner (Figure 7) . If the coronary collateral circulation had been great enough to mask any appreciable effect of neurally released NPY, it would also have markedly attenuated the increase in perfusion pressure evoked by sympathetic stimulation or by NPY infusion. Therefore, it is unlikely that an abundant collateral coronary circulation substantially masked the effects of neurally released NPY in our experiments. consumption, because myocardial oxygen consumption is such an important factor in the control of coronary vascular resistance. 23, 25 In our experiments, sympathetic stimulation did not change heart rate appreciably, and left ventricular peak systolic pressure and mean arterial pressure increased only slightly (Figure 2) . Furthermore (Figures 4 and 6) . Therefore, intense sympathetic stimulation apparently did release the expected quantities of NPY. Furthermore, the NPY receptors in the coronary vessels must have functioned normally, because our preparation did respond well to exogenous NPY (Figure 7) . Nevertheless, the amount of NPY released from the sympathetic nerve endings in the coronary vessels was evidently neither sufficient to constrict the coronary vasculature appreciably nor sufficient to potentiate the effects of NE on the coronary vasculature. In our experiments with exogenous NPY (Figure 7) , we found that we had to inject at least 1 nmol into the coronary artery to evoke a vasoconstriction that persisted for at least 10 minutes. Therefore, we conclude that the quantity of NPY released by our sympathetic release stimulations must have achieved a concentration in the coronary resistance vessels that was less than the concentration achieved by the intracoronary injection of 
